Director & 10% Owner Robert Duggan Buys $13M in Open Market
PLSE sits 54% above its 52-week low of $12.56 on elevated volume (3.0× avg).
Summary
Pulse Biosciences Director and 10% owner Robert W. Duggan purchased nearly $13 million worth of common stock in an open market transaction, signaling strong conviction.
Key Events · Ownership and Investor Activity · PLSE
-
Director & 10% Owner Makes Large Purchase
Robert W. Duggan, a Director and 10% owner, acquired 660,233 shares of common stock for approximately $13 million at an average price of $19.69 per share.
-
Significant Insider Confidence
This open market purchase, representing nearly 1% of the company's market capitalization, demonstrates strong conviction from a key insider.
-
ATM Program Used for Acquisition
The shares were acquired through the company's existing at-the-market (ATM) equity offering program, as noted in the filing footnotes.
Analysis · PLSE · Industrial Applications And Services
This significant open market purchase by Robert W. Duggan, who serves as both a Director and a 10% owner, demonstrates substantial insider confidence in Pulse Biosciences. The acquisition of nearly $13 million in shares, representing almost 1% of the company's market capitalization, is a material investment and stands out as a strong positive signal, especially following recent positive clinical data and strategic realignments.
At the time of this filing, PLSE was trading at $19.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.